MX2022009176A - Metodo y composiciones para el tratamiento de infeccion por coronavirus. - Google Patents

Metodo y composiciones para el tratamiento de infeccion por coronavirus.

Info

Publication number
MX2022009176A
MX2022009176A MX2022009176A MX2022009176A MX2022009176A MX 2022009176 A MX2022009176 A MX 2022009176A MX 2022009176 A MX2022009176 A MX 2022009176A MX 2022009176 A MX2022009176 A MX 2022009176A MX 2022009176 A MX2022009176 A MX 2022009176A
Authority
MX
Mexico
Prior art keywords
compositions
coronavirus infection
treating coronavirus
viral infection
treating
Prior art date
Application number
MX2022009176A
Other languages
English (en)
Inventor
Robert A Newman
Otis C Addington
Richard Obiso
Original Assignee
Phoenix Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/895,920 external-priority patent/US10729735B1/en
Application filed by Phoenix Biotechnology Inc filed Critical Phoenix Biotechnology Inc
Publication of MX2022009176A publication Critical patent/MX2022009176A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona un método de tratamiento de una infección viral, tal como una infección viral provocada por un virus de la familia Coronaviridae; se utiliza una composición que tiene por lo menos oleandrina para tratar la infección viral.
MX2022009176A 2020-03-31 2020-08-31 Metodo y composiciones para el tratamiento de infeccion por coronavirus. MX2022009176A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202063002735P 2020-03-31 2020-03-31
US202063010246P 2020-04-15 2020-04-15
US202063014294P 2020-04-23 2020-04-23
US202063017263P 2020-04-29 2020-04-29
US202063021512P 2020-05-07 2020-05-07
US202063029530P 2020-05-24 2020-05-24
US202063034800P 2020-06-04 2020-06-04
US16/895,920 US10729735B1 (en) 2016-09-14 2020-06-08 Method and compostitions for treating coronavirus infection
US202063042656P 2020-06-23 2020-06-23
US202063051576P 2020-07-14 2020-07-14

Publications (1)

Publication Number Publication Date
MX2022009176A true MX2022009176A (es) 2022-08-17

Family

ID=77930101

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020009095A MX2020009095A (es) 2020-03-31 2020-07-14 Metodo y composiciones para el tratamiento de infeccion por coronavirus.
MX2022009176A MX2022009176A (es) 2020-03-31 2020-08-31 Metodo y composiciones para el tratamiento de infeccion por coronavirus.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020009095A MX2020009095A (es) 2020-03-31 2020-07-14 Metodo y composiciones para el tratamiento de infeccion por coronavirus.

Country Status (8)

Country Link
JP (2) JP7153083B2 (es)
KR (2) KR102464428B1 (es)
IL (2) IL277315B (es)
MX (2) MX2020009095A (es)
RU (1) RU2020130238A (es)
SG (1) SG11202105728YA (es)
TW (2) TWI790048B (es)
WO (1) WO2021201903A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CA3228041A1 (en) * 2021-08-16 2023-02-23 Phoenix Biotechnology, Inc. Method and compositions for treating animal viral infections
WO2023212353A1 (en) * 2022-04-29 2023-11-02 Emory University Viral entry inhibitors derived from botanicals
CN115364136A (zh) * 2022-09-05 2022-11-22 深圳市药品检验研究院（深圳市医疗器械检测中心） 景天科植物提取物在制备抗新型冠状病毒和流感病毒感染药物中的应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1394196A (en) 1971-10-03 1975-05-14 Hisamitsu Pharmaceutical Co Process for isolating oleandrin from nerium odorum
MC1811A1 (fr) 1986-05-13 1988-03-18 Huseyin Ziya Ozel Extrait de plantes de l'espece nerium procede pour sa preparation et ses applications
JPS6333341A (ja) * 1986-07-28 1988-02-13 Seitetsu Kagaku Co Ltd 配糖体の処理方法
US5236132A (en) 1992-01-03 1993-08-17 Vortec, Inc. Gradient-force comminuter/dehydrator apparatus and method
US5598979A (en) 1995-04-20 1997-02-04 Vortec, Inc. Closed loop gradient force comminuting and dehydrating system
CA2191923C (en) 1996-12-03 2000-10-24 Ji-Won Yoon Portulaca oleracea and tumor cell growth
CN1307473A (zh) 1998-05-19 2001-08-08 研究发展基金会 三萜组合物和它们的使用方法
AU6056999A (en) 1998-09-24 2000-04-10 Ozelle Pharmaceuticals, Inc. Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof
US6517015B2 (en) 2000-03-21 2003-02-11 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
EP1309605A1 (en) 2000-08-18 2003-05-14 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv
US6715705B2 (en) 2001-03-16 2004-04-06 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
ATE295087T1 (de) 2001-04-09 2005-05-15 Loders Croklaan Bv Konzentrat von triterpenen
EP1476031A1 (en) 2001-05-11 2004-11-17 University of Ottawa Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
EP1397149A1 (en) 2001-06-18 2004-03-17 S.A.V Virex Co Ltd Nerium oleander extract, compositions containing the nerium oleander l. extract and a method of preparation of this extract
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
WO2004043363A2 (en) 2002-11-06 2004-05-27 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
WO2004087121A2 (en) 2003-03-28 2004-10-14 Azaya Therapeutics, Inc. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
RU2387665C2 (ru) 2004-03-17 2010-04-27 Панакос Фармасьютикалз, Инк. Фармацевтические соли 3-о-(3', 3'-диметилсукцинил)бетулиновой кислоты
US7118508B2 (en) 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
CA2575667A1 (en) 2004-08-13 2006-04-06 Biolase Technology, Inc. Laser handpiece architecture and methods
ATE486886T1 (de) 2005-02-09 2010-11-15 Dabur Pharma Ltd Neue betulinsäurederivate kondensiert im a-ring mit einer heterozyklischen gruppe
US20090076290A1 (en) 2005-03-29 2009-03-19 Regents Of The University Of Minnesota Selective oxidation of triterpenes employing tempo
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
WO2006133314A2 (en) 2005-06-08 2006-12-14 Regents Of The University Of Minnesota Synthesis of betulonic and betulinic aldehydes
RU2407748C2 (ru) 2005-06-10 2010-12-27 Пола Кемикал Индастриз Инк. Новое производное кислоты тритерпенового ряда и содержащий его препарат для наружного применения для кожи
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
TW200745155A (en) 2005-12-16 2007-12-16 Christian Hemp Preparation of pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl)betulinic acid
EP1803461A1 (en) 2005-12-27 2007-07-04 Heinz-Herbert Fiebig Therapeutic use of an extract from the leaves of Nerium oleander
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
US20090203661A1 (en) 2006-10-12 2009-08-13 Safe Stephen H Betulinic acid, derivatives and analogs thereof and uses therefor
US9505800B2 (en) 2006-11-03 2016-11-29 Myrexis, Inc. Extended triterpene derivatives
WO2008091532A1 (en) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
EP2231165B1 (en) 2007-11-13 2013-05-15 Phoenix Biotechnology Inc. Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside
KR101735807B1 (ko) 2008-04-18 2017-05-15 리타 파마슈티컬스 잉크. Ｃ-17에 아미노 및 기타 변형을 갖는 올레아놀산 유도체를 포함하는 항산화 염증 조절제
CA2721666C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
MX2010011437A (es) 2008-04-18 2010-12-20 Reata Pharmaceuticals Inc Moduladores antioxidantes de inflamacion: derivados del acido oleanolico con saturacion en el anillo c.
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CA2736568A1 (en) 2008-09-10 2010-03-18 Universite Du Quebec A Chicoutimi Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
KR101717301B1 (ko) 2008-10-14 2017-03-16 네리엄 바이오테크놀로지, 인크. 강심 배당체의 추출방법 및 조성물
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
WO2010144611A2 (en) * 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
CN101704872B (zh) 2009-11-23 2012-06-27 张南 23-羟基白桦酸衍生物、其制备方法及应用
WO2011064710A1 (en) 2009-11-30 2011-06-03 University Of Kwazulu-Natal In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
ES2638070T3 (es) 2010-01-11 2017-10-18 Phoenix Biotechnology Inc. Procedimiento para tratar afecciones neurológicas con glucósidos cardiacos
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
TWI386415B (zh) 2010-02-02 2013-02-21 Univ Kaohsiung Medical 熊果酸衍生物及其醫藥組合物
TWI410431B (zh) 2010-12-22 2013-10-01 Ind Tech Res Inst 齊敦果酸衍生物在製備預防或治療ｃ型肝炎之藥物的用途
WO2012095705A1 (en) 2011-01-10 2012-07-19 Hetero Research Foundation Pharmaceutically acceptable salts of novel betulinic acid derivatives
ES2552512T3 (es) 2011-01-31 2015-11-30 Bristol-Myers Squibb Company Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana
CN102558280B (zh) 2011-11-18 2014-09-17 温州大学 一种30-卤代桦木酸的生产方法
DK2787002T3 (en) 2011-12-01 2016-08-29 Hangzhou Bensheng Pharmaceutical Co Ltd Oleanolsyreamidat derivatives, methods of making and uses thereof
US9156801B2 (en) 2011-12-01 2015-10-13 Hangzhou Bensheng Pharmaceutical Co., Ltd. 2-substituted oleanolic acid derivative, method preparing for same, and application thereof
WO2013160810A2 (en) 2012-04-24 2013-10-31 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2014027777A2 (ko) 2012-08-14 2014-02-20 한국콜마 주식회사 신규한 우르솔릭산 유도체 및 이의 제조 방법
WO2014040060A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
KR102237364B1 (ko) 2012-09-10 2021-04-06 리아타 파마슈티컬즈, 아이엔씨. 올레아놀산의 ｃ１７―헤테로아릴 유도체 및 그의 사용 방법
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
EA027861B1 (ru) 2013-02-25 2017-09-29 Бристол-Майерс Сквибб Компани C-3 алкил- и алкенилмодифицированные производные бетулиновой кислоты или их фармацевтические соли, противовирусная фармацевтическая композиция и фармацевтическая композиция для лечения вич на их основе
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
WO2017214080A1 (en) * 2016-06-09 2017-12-14 University Of Massachusetts Inhibition of zika virus infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
EP3512524B1 (en) 2016-09-14 2021-04-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10702567B2 (en) * 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
IL285232B (en) 2017-09-14 2022-07-01 Phoenix Biotechnology Inc Preparations containing oleandrin for the treatment of viral infection

Also Published As

Publication number Publication date
JP2022522074A (ja) 2022-04-14
TWI790048B (zh) 2023-01-11
SG11202105728YA (en) 2021-11-29
KR20210124010A (ko) 2021-10-14
KR20220151038A (ko) 2022-11-11
JP2022186737A (ja) 2022-12-15
TW202137991A (zh) 2021-10-16
IL277315A (en) 2021-09-30
WO2021201903A1 (en) 2021-10-07
RU2020130238A (ru) 2022-03-14
JP7153083B2 (ja) 2022-10-13
TWI753747B (zh) 2022-01-21
IL291727B1 (en) 2023-03-01
IL291727A (en) 2022-05-01
IL277315B (en) 2022-05-01
MX2020009095A (es) 2022-07-28
IL291727B2 (en) 2023-07-01
KR102464428B1 (ko) 2022-11-04
RU2020130238A3 (es) 2022-03-14
TW202211926A (zh) 2022-04-01

Similar Documents

Publication Publication Date Title
MX2022009176A (es) Metodo y composiciones para el tratamiento de infeccion por coronavirus.
EA202193251A1 (ru) Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
AU2021260618A8 (en) Antiviral application of nucleoside analog or combination formulation containing nucleoside analog
ZA202207169B (en) Methods, compositions, and vaccines for treating a virus infection
MX2019002978A (es) Composiciones que comprenden una bacteria no patogena y metodos para proteger plantas y animales anfitriones contra enfermedades micoticas, bacterianas y virales.
UA118080C2 (uk) Противірусні сполуки
MX338530B (es) Inhibidores de molecula pequeña para el tratamiento o prevencion de infeccion de virus del dengue.
BR112023025358A2 (pt) Inibidores de protease como antivirais
BR112023020798A2 (pt) Método para tratar ou prevenir uma infecção, e, uso de um composto
MX2020002883A (es) Método y composiciones para tratar la infección viral.
MX2022013749A (es) Metodos y composiciones para el tratamiento del coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2).
MX2022011173A (es) Tratamiento de infeccion por coronavirus.
UY39146A (es) Composiciones atenuantes de piensos para inactivar virus porcinos y procedimientos relacionados
MX2022009476A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
ZA202209180B (en) Compositions and methods for treating long covid
CR20220418A (es) Compuestos tetracíclicos para el tratamiento de infecciones por vih
PH12021551062A1 (en) Method and compositions for treating coronavirus infection
UY39313A (es) Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
EA202192454A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
WO2021202103A3 (en) Method and compositions for treating coronavirus infection
MX2022010926A (es) Compuestos para su uso en infecciones viricas.
MX2021014579A (es) Metodo y composiciones para tratar una infeccion por el virus linfotropico humano de celulas t tipo 1.
WO2022032112A3 (en) Compositions and methods for treating a coronavirus infection
BR112022016177A2 (pt) Método de tratamento usando meta-arsenito